CSL Of Australia Encounters More Negative News From Flu Vaccine
This article was originally published in PharmAsia News
Executive SummaryAustralia's CSL suffered a one-two punch on the stock markets, with recall of its seasonal flu vaccine coupled with economic projections for the next year
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.